Search Results 751-760 of 16073 for pharmacogenetics

1. A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis - Mayo Clinic

   About this study. The primary objective of this study is to evaluate the safety and tolerability of BIIB078 in adults with C9ORF72-ALS.

2. FT819 in Subjects With B-cell Malignancies - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

3. Philip W. Tipton, M.D. - Doctors and Medical Staff - Mayo Clinic

   Tipton is an assistant professor and senior associate consultant in the Department of Neurology at Mayo Clinic in Jacksonville, FL, where he has served since ...

4. Evaluation of the Effects of Caffeine, Via the ACE2 Receptor, on Clinical Severity of COVID-19 Disease

   The purpose of this study is to assess levels of caffeine intake among patients who tested positive for COVID-19 infection and compare that to disease severity.

5. Todd and Karen Wanek Family Program for HLHS - Clinical Trials

   Todd and Karen Wanek Family Program for HLHS at Mayo Clinic: HLHS clinical trials on genetic screening, bone marrow, umbilical cord blood banking, more.

6. Clinical trials - Oncology (Medical)

   The purpose of this trial is to identify cancer survivors who are at increased risk of developing late-occurring complications after undergoing treatment ...

7. Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery - Mayo Clinic

   Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab and bevacizumab, ...

8. GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

9. Mayo Clinic Confirms Genetic Predictor for Fuchs' Corneal Dystrophy

   ROCHESTER, Minn. — May 4, 2012. Mayo Clinic and University of Oregon researchers have confirmed that a genetic factor called a repeating trinucleotide is a ...

10. Trial of Multi-epitope HER2 Peptide Vaccine in Patients with HER2-expressing DCIS - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...